Cargando…
Hematologic toxicity of radium-223 in elderly patients with metastatic Castration Resistant Prostate Cancer: a real-life experience
BACKGROUND: Treatment with radium-223 has been shown to increase survival and to delay skeletal events related to bone metastases of patients with metastatic Castration Resistant Prostate Cancer (mCRPC). This treatment has also proved to be well tolerated, and hematological toxicity, in particular a...
Autores principales: | Costa, Renato P., Bordonaro, Sebastiano, Cappuccio, Francesco, Tripoli, Vincenzo, Murabito, Alessandra, Licari, Maria, Valerio, Maria R., Tralongo, Paolo |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Asian Pacific Prostate Society
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6424691/ https://www.ncbi.nlm.nih.gov/pubmed/30937295 http://dx.doi.org/10.1016/j.prnil.2018.08.001 |
Ejemplares similares
-
Can radium 223 be a conservative non-surgical management of medication-related osteonecrosis of the jaw?
por: Costa, Renato Patrizio, et al.
Publicado: (2019) -
Radium-223 in metastatic castration resistant prostate cancer
por: Vuong, Winston, et al.
Publicado: (2014) -
Radium-223 and metastatic castration-resistant prostate cancer: All that glitters is not gold
por: Aprile, Carlo, et al.
Publicado: (2016) -
Dutch Economic Value of Radium-223 in Metastatic Castration-Resistant Prostate Cancer
por: Peters, Michel L., et al.
Publicado: (2017) -
Practical recommendations for radium-223 treatment of metastatic castration-resistant prostate cancer
por: Du, Yong, et al.
Publicado: (2017)